American Diabetes Association
Browse
ELIXA_Biomarker_Paper_Supplement_--_April_27_Novel_Communication_Clean.pdf (533.3 kB)

Protein Biomarkers and Cardiovascular Outcomes in People with Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study

Download (533.3 kB)
figure
posted on 2022-07-11, 22:30 authored by Hertzel C. Gerstein, Sibylle Hess, Brian Claggett, Kenneth Dickstein, Lars Kober, Aldo Pietro Maggioni, John J.V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Jean-Claude Tardif, Marc A. Pfeffer

  

Background: Protein biomarkers may identify people with type 2 diabetes at high risk of cardiovascular outcomes and death. 

Methods:  Bio-banked serum from 4957 ELIXA (Evaluating Lixisenatide in Acute Coronary Syndrome) participants was analyzed. Forward-selection Cox models identified independent protein risk factors for major adverse cardiovascular events (MACE) and death, that were compared to a previously validated biomarker panel. 

Results: NT-proBNP and osteoprotegerin predicted both outcomes. In addition, trefoil factor 3 predicted MACE, and angiopoietin-2 predicted death (C = 0.70 and 0.79 respectively compared to 0.63 and 0.66 for clinical variables alone). These proteins had all been previously identified and validated. Notably, C statistics for just NT-proBNP plus clinical risk factors were 0.69 and 0.78 for MACE and death respectively. 

Conclusion: NT-proBNP and other proteins independently predict CV outcomes in people with type 2 diabetes following acute coronary syndrome. Adding other biomarkers only marginally increased NT-proBNP’s prognostic value.  


Funding

The ELIXA trial as well as the ELIXA biomarker substudy was funded by Sanofi.

History

Usage metrics

    Diabetes Care

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC